Literature DB >> 23139948

Medicare program; end-stage renal disease prospective payment system, quality incentive program, and bad debt reductions for all Medicare providers. Final rule.

.   

Abstract

This final rule updates and makes revisions to the end-stage renal disease (ESRD) prospective payment system (PPS) for calendar year (CY) 2013. This rule also sets forth requirements for the ESRD quality incentive program (QIP), including for payment year (PY) 2015 and beyond. In addition, this rule implements changes to bad debt reimbursement for all Medicare providers, suppliers, and other entities eligible to receive Medicare payment for bad debt and removes the cap on bad debt reimbursement to ESRD facilities. (See the Table of Contents for a listing of the specific issues addressed in this final rule.)

Entities:  

Mesh:

Year:  2012        PMID: 23139948

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  15 in total

1.  Improving outcomes for ESRD patients: shifting the quality paradigm.

Authors:  Allen R Nissenson
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-07       Impact factor: 8.237

2.  Integrating Quality Improvement Education into the Nephrology Curricular Milestones Framework and the Clinical Learning Environment Review.

Authors:  Lisa K Prince; Dustin J Little; Katherine I Schexneider; Christina M Yuan
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-10       Impact factor: 8.237

3.  Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS.

Authors:  Rachel B Fissell; Angelo Karaboyas; Brian A Bieber; Ananda Sen; Yun Li; Antonio A Lopes; Takashi Akiba; Jürgen Bommer; Jean Ethier; Michel Jadoul; Ronald L Pisoni; Bruce M Robinson; Francesca Tentori
Journal:  Hemodial Int       Date:  2015-05-14       Impact factor: 1.812

4.  Do socioeconomic factors affect dialysis modality selection?

Authors:  Gihad Nesrallah; Braden Manns
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

5.  CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis.

Authors:  Geoffrey A Block; Ryan D Kilpatrick; Kimberly A Lowe; Wenli Wang; Mark D Danese
Journal:  Clin J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 8.237

6.  Five policies to promote palliative care for patients with ESRD.

Authors:  Manjula Kurella Tamura; Diane E Meier
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-06       Impact factor: 8.237

7.  Guiding principles and checklist for population-based quality metrics.

Authors:  Mahesh Krishnan; Steven M Brunelli; Franklin W Maddux; Thomas F Parker; Douglas Johnson; Allen R Nissenson; Allan Collins; Eduardo Lacson
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 8.237

8.  The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients.

Authors:  Abhijit V Kshirsagar; Janet K Freburger; Alan R Ellis; Lily Wang; Wolfgang C Winkelmayer; M Alan Brookhart
Journal:  Am J Med       Date:  2013-04-15       Impact factor: 4.965

Review 9.  Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide.

Authors:  Amanda Valliant; R Michael Hofmann
Journal:  Int J Nanomedicine       Date:  2013-08-26

10.  Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients.

Authors:  Abhijit V Kshirsagar; Janet K Freburger; Alan R Ellis; Lily Wang; Wolfgang C Winkelmayer; M Alan Brookhart
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.